Need help choosing the right code?
Ask CasePilot about procedures, modifiers, bundling, and coding guidance.
Try CasePilot© Copyright 2026 American Medical Association. All rights reserved.
The CPT® Code 80371 refers to a laboratory test specifically designed to measure synthetic stimulants in urine. Synthetic stimulants are a class of drugs that include substances such as methylenedioxypyrovalerone (MDPV), mephedrone (commonly known as Meph or MCat), Butylone (bk-MBDB), cathinone (Khat), ethylone (MDEC, bk-MDEA), benzylpiperazine (BZP), meta-chlorophenylpiperazine (mCPP), and 3-Trifluoromethylphenylpiperazine (TFMPP). These substances are not indicated for any medical use and are primarily associated with recreational abuse. The mechanism of action for these synthetic stimulants involves the inhibition of neurotransmitter removal—specifically dopamine, norepinephrine, and serotonin—at the synapses in the brain. This inhibition can lead to a range of effects, including euphoria, increased physical activity, prolonged wakefulness, and in some cases, severe psychological symptoms such as hallucinations and delusions, which may result in violent behavior towards oneself or others. The testing process involves obtaining a urine sample, which can be collected through random voiding or catheterization. The sample is then analyzed using advanced techniques such as gas chromatography/mass spectrometry or quantitative high-performance liquid chromatography/tandem mass spectrometry, particularly when testing for MDPV.
© Copyright 2026 Coding Ahead. All rights reserved.
The laboratory test represented by CPT® Code 80371 is indicated for the detection of synthetic stimulants in urine. These substances are often associated with recreational drug use and have no recognized medical applications. The test is particularly relevant in scenarios where there is a suspicion of synthetic stimulant abuse, which may manifest through various behavioral or psychological symptoms.
The procedure for conducting the test under CPT® Code 80371 involves several key steps to ensure accurate detection of synthetic stimulants in urine. First, a urine sample is obtained from the patient. This can be done through a random void, where the patient provides a sample spontaneously, or through catheterization, which involves inserting a catheter into the bladder to collect urine directly. Once the sample is collected, it is prepared for analysis. The testing process typically employs advanced laboratory techniques such as gas chromatography/mass spectrometry (GC/MS) or quantitative high-performance liquid chromatography/tandem mass spectrometry (HPLC/MS/MS). These methods are highly sensitive and specific, allowing for the precise identification and quantification of synthetic stimulants, including MDPV and other related substances. The results of the analysis will indicate the presence or absence of these drugs in the urine sample, providing critical information for further evaluation and management of the individual being tested.
After the completion of the testing procedure associated with CPT® Code 80371, the urine sample is analyzed, and results are generated. The expected outcome is a report indicating the presence or absence of synthetic stimulants in the urine. If synthetic stimulants are detected, further evaluation may be necessary to assess the implications of the findings, including potential treatment options or interventions for substance abuse. It is important for healthcare professionals to interpret the results in the context of the patient's clinical presentation and history. Additionally, proper documentation of the testing process and results is essential for compliance and future reference.
| Short Descr | STIMULANTS SYNTHETIC | Medium Descr | DRUG SCREENING STIMULANTS SYNTHETIC | Long Descr | Stimulants, synthetic | Status Code | Not Valid for Medicare Purposes | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Code Not Recognized by OPPS when submitted on Outpatient Hospital Part B Bill Type (12x/13x) | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T2D - Other tests - other | MUE | 1 |
| 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2015-01-01 | Added | Added |
Get instant expert-level medical coding assistance.